KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacira BioSciences (PCRX) Non-Current Deffered Revenue (2016 - 2022)

Pacira BioSciences has reported Non-Current Deffered Revenue over the past 10 years, most recently at $10.1 million for Q1 2022.

  • Quarterly results put Non-Current Deffered Revenue at $10.1 million for Q1 2022, changed N/A from a year ago — trailing twelve months through Mar 2022 was $10.1 million (changed N/A YoY), and the annual figure for FY2021 was $10.1 million, changed.
  • Non-Current Deffered Revenue for Q1 2022 was $10.1 million at Pacira BioSciences, roughly flat from $10.1 million in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for PCRX hit a ceiling of $10.1 million in Q4 2021 and a floor of $10.1 million in Q4 2021.